The Microbiome in COPD: Emerging Potential for Microbiome-Targeted Interventions

References

• Dima E, Kyriakoudi A, Kaponi M, et al. The lung microbiome dynamics between stability and exacerbation in chronic obstructive pulmonary disease (COPD): current perspectives. Respir Med. 2019;157:1–6. doi:10.1016/j.rmed.2019.08.012
   PubMed Web of Science ®Google Scholar
• Budden KF, Shukla SD, Rehman SF, et al. Functional effects of the microbiota in chronic respiratory disease. Lancet Respir Med. 2019;7(10):907–920. doi:10.1016/S2213-2600(18)30510-1
   PubMed Web of Science ®Google Scholar
• Dickson RP, Erb-Downward JR, Freeman CM, et al. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann Am Thorac Soc. 2015;12(6):821–830. doi:10.1513/AnnalsATS.201501-029OC
   PubMed Web of Science ®Google Scholar
• Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med. 2011;184(8):957–963. doi:10.1164/rccm.201104-0655OC
   PubMed Web of Science ®Google Scholar
• Bassis CM, Erb-Downward JR, Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. mBio. 2015;6(2):e0037–e15. doi:10.1128/mBio.00037-15
   PubMed Web of Science ®Google Scholar
• Charlson ES, Chen J, Custers-Allen R, et al. Disordered microbial communities in the upper respiratory tract of cigarette smokers. PLosOne. 2010;5(12):e15216. doi:10.1371/journal.pone.0015216
   PubMed Web of Science ®Google Scholar
• Morris A, Beck JM, Schloss PD, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med. 2013;187(10):1067–1075. doi:10.1164/rccm.201210-1913OC
   PubMed Web of Science ®Google Scholar
• Wu J, Peters BA, Dominianni C, et al. Cigarette smoking and the oral microbiome in a large study of American adults. ISME J. 2016;10:2435–2446. doi:10.1038/ismej.2016.37
   PubMed Web of Science ®Google Scholar
• Mayhew D, Devos N, Lambert C, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018;73(5):422–430. doi:10.1136/thoraxjnl-2017-210408
   PubMed Web of Science ®Google Scholar
• Li KJ, Chen ZL, Huang Y, et al. Dysbiosis of lower respiratory tract microbiome are associated with inflammation and microbial function variety. Respir Res. 2019;20(1):272. doi:10.1186/s12931-019-1246-0
   PubMed Web of Science ®Google Scholar
• Garcia-Nuñez M, Millares L, Pomares X, et al. Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52(12):4217–4223. doi:10.1128/JCM.01967-14
   PubMed Web of Science ®Google Scholar
• Millares L, Pascual S, Montón C, et al. Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients. BMC Pulm Med. 2019;19(1):112. doi:10.1186/s12890-019-0867-x
   PubMed Web of Science ®Google Scholar
• Einarsson GG, Comer DM, McIIreavey L, et al. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax. 2016;71(9):795–803. doi:10.1136/thoraxjnl-2015-207235
   PubMed Web of Science ®Google Scholar
• Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One. 2012;7(10):e47305. doi:10.1371/journal.pone.0047305
   PubMed Web of Science ®Google Scholar
• Cabrera-Rubio R, García-Núñez M, Setó L, et al. A Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. J Clin Microbiol. 2012;50(11):3562–3568. doi:10.1128/JCM.00767-12
   PubMed Web of Science ®Google Scholar
• Huang YJ, Kim E, Cox MJ, et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS. 2010;14(1):9–59. doi:10.1089/omi.2009.0100
   PubMed Web of Science ®Google Scholar
• Jubinville E, Veillette M, Milot J, et al. Exacerbation induces a microbiota shift in sputa of COPD patients. PLoS One. 2018;13(3):e0194355. doi:10.1371/journal.pone.0194355
   PubMed Web of Science ®Google Scholar
• Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52(8):2813. doi:10.1128/JCM.00035-14
   PubMed Web of Science ®Google Scholar
• Millares L, Ferrari R, Gallego M, et al. Bronchial microbiome of severe COPD patients colonized by Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2014;33(7):1101–1111. doi:10.1007/s10096-013-2044-0
   PubMed Web of Science ®Google Scholar
• Huang YJ, Boushey HA. The sputum microbiome in chronic obstructive pulmonary disease exacerbations. Ann Am Thorac Soc. 2015;12(Suppl 2):S176–S180. doi:10.1513/AnnalsATS.201506-319AW
   PubMed Web of Science ®Google Scholar
• Jakobsson HE, Jernberg C, Andersson AF, Sjölung-Karlsoson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836. doi:10.1371/journal.pone.0009836
   PubMed Web of Science ®Google Scholar
• Bouquet J, Tabor DE, Silver JS, et al. Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort. Respir Res. 2020;21(1):77. doi:10.1186/s12931-020-01340-0
   PubMed Web of Science ®Google Scholar
• Dicker AJ, Huang JTJ, Lonergan M, et al. The sputum microbiome, airway inflammation and mortality in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2021;147(1):158–167. doi:10.1016/j.jaci.2020.02.040
   PubMed Web of Science ®Google Scholar
• Eltboli O, Mistry V, Barker B, Brightling CE. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology. 2015;20(4):667–670. doi:10.1111/resp.12475
   PubMed Web of Science ®Google Scholar
• Negewo NA, McDonald VM, Baines KJ, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J COPD. 2016;11:1495–1504. doi:10.2147/COPD.S100338
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD Reports. Available from: https://goldcopd.org/2022-gold-reports-2. Accessed June 1, 2022.
   Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55. doi:10.1164/rccm.201108-1553OC
   PubMed Web of Science ®Google Scholar
• Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019;7(8):699–709. doi:10.1016/S2213-2600(19)30176-6
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–1066. doi:10.1001/jama.2009.1297
   PubMed Web of Science ®Google Scholar
• Schuetz P, Müller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012;2012(9):CD007498.
   PubMedGoogle Scholar
• Wang JX, Zhang SM, Li XH, Zhang Y, Xu ZY, Cao B. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. Int J Infect Dis. 2016;48:40–45. doi:10.1016/j.ijid.2016.04.024
   PubMed Web of Science ®Google Scholar
• Albert RK, Connet J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa1104623
   PubMed Web of Science ®Google Scholar
• Segal LN, Clemente JC, Wu BG, et al. Randomized, double-blind, placebo-controlled trial with azithromycin select for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax. 2017;72(1):13–22. doi:10.1136/thoraxjnl-2016-208599
   PubMed Web of Science ®Google Scholar
• Contoli M, Pauletti A, Rossi MR, et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50(4):1700451. doi:10.1183/13993003.00451-2017
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(8):1090–1095. doi:10.1164/rccm.200210-1179OC
   PubMed Web of Science ®Google Scholar
• Garcha DS, Thurston SJ, Patel ARC, et al. Changes in the prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67(12):1075–1080. doi:10.1136/thoraxjnl-2012-201924
   PubMed Web of Science ®Google Scholar
• Ditz B, Christenson S, Rossen J, et al. Sputum microbiome profiling in COPD: beyond singular pathogen detection. Thorax. 2020;75(4):338–344. doi:10.1136/thoraxjnl-2019-214168
   PubMed Web of Science ®Google Scholar
• Tagg JR, Dierksen KP. Bacterial replacement therapy: adapting “germ warfare” to infection prevention. Trends Biotechnol. 2003;21(5):217–223. doi:10.1016/S0167-7799(03)00085-4
   PubMed Web of Science ®Google Scholar
• Shukla SD, Budden KF, Neal R, Hansbro PM. Microbiome effects on immunity, health and disease in the lung. Clin Transl Immunol. 2017;6(3):e133. doi:10.1038/cti.2017.6
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(10):1224–1231. doi:10.1164/rccm.201302-0341OC
   PubMed Web of Science ®Google Scholar
• Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J. 2016;47(4):1082–1092. doi:10.1183/13993003.01406-2015
   PubMed Web of Science ®Google Scholar
• Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet. 2014;384(9944):691–702. doi:10.1016/S0140-6736(14)61136-3
   PubMed Web of Science ®Google Scholar
• Ghebre MA, Pang PH, Diver S, et al. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. J Allergy Clin Immunol. 2018;141(6):2027–2036. doi:10.1016/j.jaci.2018.04.013
   PubMed Web of Science ®Google Scholar
• Haldar K, Bafadhel M, Lau K, et al. Microbiome balance in sputum determined by PCR stratifies COPD exacerbations and shows potential for selective use of antibiotics. PLoS One. 2017;12(8):e0182833. doi:10.1371/journal.pone.0182833
   PubMed Web of Science ®Google Scholar
• Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype- associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations. A multicohort longitudinal analysis. Am J Respir Crit Care Med. 2021;203(12):1488–1502. doi:10.1164/rccm.202009-3448OC
   PubMed Web of Science ®Google Scholar
• Beech AS, Lea S, Kolsum U, et al. Bacteria and sputum inflammatory cell counts; a COPD cohort analysis. Respir Res. 2020;21(1):289. doi:10.1186/s12931-020-01552-4
   PubMed Web of Science ®Google Scholar
• Mannion JM, McLoughlin RM, Lalor SJ. The airway microbiome-IL-17 axis: a critical regulator of chronic inflammatory disease. Clin Rev Allergy Immunol. 2022. doi:10.1007/s12016-022-08928-y
   PubMed Web of Science ®Google Scholar
• Leitao Filho FS, Alotaibi NM, Ngan D, et al. Sputum microbiome is associated with 1-year mortality after chronic obstructive pulmonary disease hospitalizations. Am J Respir Crit Care Med. 2019;199(10):1205–1213. doi:10.1164/rccm.201806-1135OC
   PubMed Web of Science ®Google Scholar
• Rigauts C, Aizawa J, Taylor S, et al. Rothia mucilaginosa is an antiinflammatory bacterium in the respiratory tract of patients with chronic lung disease. Eur Respir J. 2022;59. doi:10.1183/13993003.01293-2021
   PubMed Web of Science ®Google Scholar
• Rogers GB, Zain NMM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc. 2014;11(4):496–503. doi:10.1513/AnnalsATS.201310-335OC
   PubMedGoogle Scholar
• Duan K, Dammel C, Stein J, Rabin H, Surette MG. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol. 2003;50(5):1477–1491. doi:10.1046/j.1365-2958.2003.03803.x
   PubMed Web of Science ®Google Scholar
• Iwase T, Uehara Y, Shinji H, et al. Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature. 2010;465(7296):346–349. doi:10.1038/nature09074
   PubMed Web of Science ®Google Scholar
• Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS One. 2011;6(2):e16384. doi:10.1371/journal.pone.0016384
   PubMed Web of Science ®Google Scholar
• Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. 2014;20(2):159–166. doi:10.1038/nm.3444
   PubMed Web of Science ®Google Scholar
• Wang Z, Maschera B, Lea S, et al. Airway host-microbiome interactions in chronic obstructive pulmonary disease. Respir Res. 2019;20(1):113. doi:10.1186/s12931-019-1085-z
   PubMed Web of Science ®Google Scholar
• Limoli DH, Hoffman LR. Help, hinder, hide and harm: what can we learn from the interactions between Pseudomonas aeruginosa and Staphylococcus aureus during respiratory infections? Thorax. 2019;74(7):684–692. doi:10.1136/thoraxjnl-2018-212616
   PubMed Web of Science ®Google Scholar
• Sundh J, Tanash H, Arian R, et al. Advanced dental cleaning is associated with reduced risk of COPD exacerbations. A randomized controlled trial. Int J COPD. 2021;16:3203–3215. doi:10.2147/COPD.S327036
   Google Scholar
• Pragman AA, Fieberg AM, Reilly CS, Wendt C. Chlorhexidine oral rinses for symptomatic COPD: a randomised, blind, placebo-controlled preliminary study. BMJ Open. 2021;11(12):e50271. doi:10.1136/bmjopen-2021-050271
   Web of Science ®Google Scholar
• Chiu YC, Lee SW, Liu CW, Lan TY, Shih-Hsin WL. Relationship between gut microbiota and lung function decline in patients with chronic obstructive pulmonary disease: q 1-year follow-up study. Respir Res. 2022;23:10. doi:10.1186/s12931-022-01928-8
   PubMed Web of Science ®Google Scholar
• Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012;5(1):7–18. doi:10.1038/mi.2011.55
   PubMed Web of Science ®Google Scholar
• Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases. Cell Microbiol. 2018;20(12):e12966. doi:10.1111/cmi.12966
   PubMed Web of Science ®Google Scholar
• Kolenbrander PE, Palmer RJ, Periasamy S, Jakubovics NS. Oral multispecies biofilm development and the key role of cell-cell distance. Nat Rev Microbiol. 2010;8(7):471–480. doi:10.1038/nrmicro2381
   PubMed Web of Science ®Google Scholar
• Lai HC, Lin TL, Chen TW, et al. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide. Gut. 2022;71(2):309–321. doi:10.1136/gutjnl-2020-322599
   PubMed Web of Science ®Google Scholar
• Gollwitzer ES, Marsland BJ. Microbiota abnormalities in inflammatory airway diseases - Potential for therapy. Pharmacol Ther. 2014;141(1):32–39. doi:10.1016/j.pharmthera.2013.08.002
   PubMed Web of Science ®Google Scholar
• Hougee S, Vriesema AJM, Wijering SC, et al. Oral treatment with probiotics reduces allergic symptoms in ovalbumin-sensitized mice: a bacterial strain comparative study. Int Arch Allergy Immunol. 2010;151(2):107–117. doi:10.1159/000236000
   PubMed Web of Science ®Google Scholar
• Sagar S, Morgan ME, Chen S, et al. Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma. Respir Res. 2014;15(1):46. doi:10.1186/1465-9921-15-46
   PubMed Web of Science ®Google Scholar
• Devereux G. The increase in the prevalence of asthma and allergy: food for thought. Nat Rev Immunol. 2006;6(1):869–874. doi:10.1038/nri1958
   PubMed Web of Science ®Google Scholar
• Noverr MC, Huffnagle GB. The “microflora hypothesis” of allergic diseases. Clin Exp Allergy. 2005;35(12):1511–1520. doi:10.1111/j.1365-2222.2005.02379.x
   PubMed Web of Science ®Google Scholar
• Huffnagle GB. Increase in dietary fiber dampens allergic responses in the lung. Nat Med. 2014;20(2):120–121. doi:10.1038/nm.3472
   PubMed Web of Science ®Google Scholar
• Cummings JH, Hill MJ, Bone ES, Branch WJ, Jenkins DJ. The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. Am J Clin Nutr. 1979;32(10):2094–2101. doi:10.1093/ajcn/32.10.2094
   PubMed Web of Science ®Google Scholar
• Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28(1):1221–1227. doi:10.1136/gut.28.10.1221
   PubMed Web of Science ®Google Scholar
• Flint HJ, Bayer EA, Rincon MT, Lamed R, White BA. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol. 2008;6(2):121–131. doi:10.1038/nrmicro1817
   PubMed Web of Science ®Google Scholar
• Vaughan A, Frazer ZA, Hansbro PM, Yang IA. COPD and the gut-lung axis: the therapeutic potential of fibre. J Thorac Dis. 2019;11(suppl 17):S2173–S2180. doi:10.21037/jtd.2019.10.40
   PubMed Web of Science ®Google Scholar
• Li N, Dai Z, Wang Z, et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease. Respir Res. 2021;22:274. doi:10.1186/s12931-021-01872-z
   PubMed Web of Science ®Google Scholar
• Jang YO, Kim OH, Kim SJ, et al. High-fiber diets attenuate emphysema development via modulation of gut microbiota and metabolism. Sci Rep. 2021;11(1):7008. doi:10.1038/s41598-021-86404-x
   PubMed Web of Science ®Google Scholar